These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3291288)

  • 1. Influence of infusion duration on the efficacy and toxicity of intravenous cyclosporine in bone marrow transplant patients.
    McGuire TR; Tallman MS; Yee GC; Nemunaitis JJ; Higano CS; McGuffin RW; Singer JW
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):501-4. PubMed ID: 3291288
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients.
    Tallman MS; Nemunaitis JJ; McGuire TR; Yee GC; Hughes TE; Almgren JD; Appelbaum FR; Higano CS; McGuffin RW; Singer JW
    Transplantation; 1988 Apr; 45(4):810-3. PubMed ID: 3282363
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.
    Yee GC; McGuire TR; St Pierre BA; Self SG; Zager RA; Sullivan KM; Deeg HJ
    Bone Marrow Transplant; 1989 Nov; 4(6):691-4. PubMed ID: 2684309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine administration practices on bone marrow transplant units: a national survey.
    Caudell KA; Adams J
    Oncol Nurs Forum; 1990; 17(4):563-8. PubMed ID: 2119035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous cyclosporine to induce immunosuppression in cardiac allograft recipients.
    Macris MP; Frazier OH; Van Buren CT; Duncan JM
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):311-5. PubMed ID: 3291261
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients.
    Dieterle A; Gratwohl A; Nizze H; Huser B; Mihatsch MJ; Thiel G; Tichelli A; Signer E; Nissen C; Speck B
    Transplantation; 1990 Jun; 49(6):1093-100. PubMed ID: 2193442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo accelerated hypertension during sequential cyclosporine and prednisone therapy in normotensive bone marrow transplant recipients.
    Textor SC; Forman SJ; Bravo EL; Carlson J
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):480-6. PubMed ID: 3291284
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclosporine and graft-versus-host disease after bone marrow transplantation.
    N Engl J Med; 1988 Dec; 319(24):1607-8. PubMed ID: 3059188
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW; Wozniak SP
    Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the safety and efficacy of oral vs constant-rate intravenous infusion cyclosporine immediately following orthotopic heart transplantation.
    Myre SA; Schroeder TJ; Melvin DB; Pesce AJ; Collins JA; Stephens GW; First MR
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2484-6. PubMed ID: 2650310
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients.
    Lindholm A; Ringdén O; Lönnqvist B
    Transplantation; 1987 May; 43(5):680-4. PubMed ID: 3554661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine A administration: once a day or in fractional doses?
    Dieperink H; Leyssac PP; Starklint H; Kemp E
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):703-6. PubMed ID: 3284118
    [No Abstract]   [Full Text] [Related]  

  • 14. Age-related factors in the induction of syngeneic GVHD.
    Fischer AC; Beschorner WE; Hess AD
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3033-5. PubMed ID: 2650419
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD; Shore TB; Reece DE; Barnett MJ; Klingemann HG; Buskard NA; Phillips GL
    Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membranous nephropathy in a bone marrow transplant recipient.
    Hiesse C; Goldschmidt E; Santelli G; Charpentier B; Machover D; Fries D
    Am J Kidney Dis; 1988 Feb; 11(2):188-91. PubMed ID: 3277409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC; LeMaistre CF; Zagars GK; Williams LA; Meneghetti CM; Luke DR; Dunphy FR; Spinolo JA; Jagannath S; Spitzer G
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with continuous high-dose intravenous cyclosporine following clinical intestinal transplantation.
    Grant D; Sommerauer J; Mimeault R; Garcia B; Ghent C; Zhong R; Stiller C; Duff J
    Transplantation; 1989 Jul; 48(1):151-2. PubMed ID: 2749888
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation.
    Yee GC
    Transplant Proc; 1990 Jun; 22(3):1327-30. PubMed ID: 2190394
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine in children.
    Polchi P; Lucarelli G; Galimberti M; Moretti L
    Prog Clin Biol Res; 1989; 309():333-48. PubMed ID: 2675102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.